{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:23Z","timestamp":1790612123468,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119301","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:35:25Z","timestamp":1775514925000},"page":"119301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immune\u2013endothelial crosstalk in cardiovascular inflammation: Canakinumab at the intersection of mechanism and precision therapy"],"prefix":"10.1016","volume":"198","author":[{"given":"Arti","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drishya","family":"Dinesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagriti","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmavir Singh","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.biopha.2026.119301_bib1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, Regional, and National burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023","volume":"86","author":"Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2026.119301_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/10742484231189597","article-title":"Residual atherosclerotic cardiovascular disease risk: focus on non-high-density lipoprotein cholesterol","volume":"28","author":"Luo","year":"2023","journal-title":"J. Cardiovasc Pharm. Ther."},{"key":"10.1016\/j.biopha.2026.119301_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur. J. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2026.119301_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11883-019-0778-6","article-title":"Recent updates on the use of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease","volume":"21","author":"Dixon","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.biopha.2026.119301_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1264319","article-title":"High residual cardiovascular risk after lipid-lowering: prime time for predictive, preventive, personalized, participatory, and psycho-cognitive medicine","volume":"10","author":"Reijnders","year":"2023","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.biopha.2026.119301_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1389106","article-title":"Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia","volume":"11","author":"Bashir","year":"2024","journal-title":"Front Cardiovasc Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119301_bib7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacl.2017.06.015","article-title":"Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis","volume":"11","author":"Wong","year":"2017","journal-title":"J. Clin. Lipido"},{"issue":"21","key":"10.1016\/j.biopha.2026.119301_bib8","doi-asserted-by":"crossref","first-page":"12906","DOI":"10.3390\/ijms232112906","article-title":"The role of inflammation in cardiovascular disease","volume":"23","author":"Henein","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119301_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40119-024-00376-3","article-title":"Recent advances in targeted management of inflammation in atherosclerosis: a narrative review","volume":"13","author":"Zubir\u00e1n","year":"2024","journal-title":"Cardiol. Ther."},{"key":"10.1016\/j.biopha.2026.119301_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106157","article-title":"Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis","volume":"178","author":"Hafiane","year":"2022","journal-title":"Pharm. Res"},{"issue":"6","key":"10.1016\/j.biopha.2026.119301_bib11","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1161\/ATVBAHA.120.314330","article-title":"Vascular endothelial cells and innate immunity","volume":"40","author":"Shao","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119301_bib12","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3390\/ijms26041708","article-title":"The interplay between immunity, inflammation and endothelial dysfunction","volume":"26","author":"Chee","year":"2025","journal-title":"Int J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.biopha.2026.119301_bib13","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1007\/s00018-013-1289-1","article-title":"Inflammation and immune system interactions in atherosclerosis","volume":"70","author":"Legein","year":"2013","journal-title":"Cell Mol. Life Sci."},{"issue":"12","key":"10.1016\/j.biopha.2026.119301_bib14","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ. Res"},{"issue":"2","key":"10.1016\/j.biopha.2026.119301_bib15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/cvr\/cvab010","article-title":"NLRP3 inflammasome as a key driver of vascular disease","volume":"118","author":"Takahashi","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"10105","key":"10.1016\/j.biopha.2026.119301_bib16","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"issue":"10118","key":"10.1016\/j.biopha.2026.119301_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00395-022-00969-w","article-title":"Clonal hematopoiesis and cardiovascular disease: deciphering interconnections","volume":"117","author":"Stein","year":"2022","journal-title":"Basic Res Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11897-025-00710-3","article-title":"Inflammatory biomarkers in heart failure: clinical perspectives on hsCRP, IL-6 and emerging candidates","volume":"22","author":"Kurt","year":"2025","journal-title":"Curr. Heart Fail Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s44313-025-00065-7","article-title":"Clonal hematopoiesis: elements associated with clonal expansion and diseases","volume":"60","author":"Ryu","year":"2025","journal-title":"Blood Res"},{"issue":"3","key":"10.1016\/j.biopha.2026.119301_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/antiox11030543","article-title":"Oxidative stress, vascular endothelium, and the pathology of neurodegeneration in retina","volume":"11","author":"Shi","year":"2022","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/07853890.2011.645498","article-title":"Bv. Vascular aging: chronic oxidative stress and impairment of redox signaling consequences for vascular homeostasis and disease","volume":"45","author":"Bachschmid","year":"2013","journal-title":"Ann. Med"},{"issue":"3","key":"10.1016\/j.biopha.2026.119301_bib23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/antiox14030256","article-title":"Endothelial dysfunction: redox imbalance, NLRP3 inflammasome, and inflammatory responses in cardiovascular diseases","volume":"14","author":"Penna","year":"2025","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.biopha.2026.119301_bib24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cell.2020.01.015","article-title":"Single-cell transcriptome atlas of murine endothelial cells","volume":"180","author":"Kalucka","year":"2020","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.biopha.2026.119301_bib25","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1161\/CIRCULATIONAHA.119.041433","article-title":"Single-cell RNA sequencing unveils unique transcriptomic signatures of organ-specific endothelial cells","volume":"142","author":"Paik","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119301_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.matbio.2025.01.003","article-title":"Endothelial cell (EC)-specific Ctgf\/Ccn2 expression increases EC reprogramming and atherosclerosis","volume":"136","author":"Li","year":"2025","journal-title":"Matrix Biol."},{"key":"10.1016\/j.biopha.2026.119301_bib27","article-title":"NLRP3 inflammasome in atherosclerosis: mechanisms and targeted therapies","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2026.119301_bib28","article-title":"Single-cell atlas of endothelial cells in atherosclerosis: identifying C1 CXCL12+ ECs as key proliferative drivers for immunological precision therapeutics in atherosclerosis","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2026.119301_bib29","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91729","article-title":"Single-cell 'omic profiles of human aortic endothelial cells in vitro and human atherosclerotic lesions ex vivo reveal heterogeneity of endothelial subtype and response to activating perturbations","volume":"12","author":"Adelus","year":"2024","journal-title":"Elife"},{"issue":"11","key":"10.1016\/j.biopha.2026.119301_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2023-255332","article-title":"Coeliac axis thrombosis and acute hepatic failure in a patient with dilated cardiomyopathy","volume":"16","author":"Imtiaz","year":"2023","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.biopha.2026.119301_bib31","article-title":"Research progress on Th17 and T regulatory cells and their cytokines in regulating atherosclerosis","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.biopha.2026.119301_bib32","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/biomedicines12081844","article-title":"T-cell metabolic reprogramming in atherosclerosis","volume":"12","author":"Chang","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119301_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100369","article-title":"Metabolic regulation of Th17 and Treg cell balance by the mTOR signaling","volume":"26","author":"Wang","year":"2025","journal-title":"Metab. Open"},{"issue":"9","key":"10.1016\/j.biopha.2026.119301_bib34","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1161\/CIRCRESAHA.120.315931","article-title":"Neutrophil extracellular traps participate in cardiovascular diseases: recent experimental and clinical insights","volume":"126","author":"D\u00f6ring","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2026.119301_bib35","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.107742","article-title":"Xcr1+ type 1 conventional dendritic cells are essential mediators for atherosclerosis progression","volume":"14","author":"Li","year":"2025","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.biopha.2026.119301_bib36","first-page":"206","article-title":"Systematic review on the role of IL-6 and IL-1\u03b2 in cardiovascular diseases","volume":"11","author":"Katkenov","year":"2024","journal-title":"J. Cardiovasc Dev. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2026.119301_bib37","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/diagnostics15081033","article-title":"Endothelial function and pro-inflammatory cytokines as prognostic markers in acute coronary syndromes","volume":"15","author":"Tsalamandris","year":"2025","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/cvr\/cvad158","article-title":"TNF-\u03b1 protects from exacerbated myocarditis and cardiac death by suppressing expansion of activated heart-reactive CD4+ T cells","volume":"120","author":"Rolski","year":"2024","journal-title":"Cardiovasc Res."},{"issue":"8","key":"10.1016\/j.biopha.2026.119301_bib39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/cvr\/cvae071","article-title":"Endothelial nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome regulation in atherosclerosis","volume":"120","author":"Guo","year":"2024","journal-title":"Cardiovasc Res."},{"issue":"13","key":"10.1016\/j.biopha.2026.119301_bib40","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/cvr\/cvad130","article-title":"Targeting endothelial vascular cell adhesion molecule-1 in atherosclerosis: drug discovery and development of vascular cell adhesion molecule-1-directed novel therapeutics","volume":"119","author":"Pickett","year":"2023","journal-title":"Cardiovasc Res."},{"issue":"18","key":"10.1016\/j.biopha.2026.119301_bib41","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.123.065597","article-title":"Clonal hematopoiesis of indeterminate potential with loss of Tet2 enhances risk for atrial fibrillation through Nlrp3 inflammasome activation","volume":"149","author":"Lin","year":"2024","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.biopha.2026.119301_bib42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41419-020-02985-x","article-title":"NLRP3 inflammasome in endothelial dysfunction","volume":"11","author":"Bai","year":"2020","journal-title":"Cell Death Dis."},{"issue":"13","key":"10.1016\/j.biopha.2026.119301_bib43","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1093\/cvr\/cvab337","article-title":"Interleukin-1\u03b2 suppression dampens inflammatory leucocyte production and uptake in atherosclerosis","volume":"118","author":"Hettwer","year":"2022","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.biopha.2026.119301_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1550226","article-title":"NLRP3 inflammasome in cardiovascular diseases: an update","volume":"16","author":"Mo","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12929-024-01032-7","article-title":"Targeting NLRP3 signaling reduces myocarditis-induced arrhythmogenesis and cardiac remodeling","volume":"31","author":"Chin","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2026.119301_bib46","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1161\/ATVBAHA.117.309575","article-title":"NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein e-deficient mice-brief report","volume":"37","author":"Van der Heijden","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2026.119301_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1356023","article-title":"Role of inflammation and evidence for the use of colchicine in patients with acute coronary syndrome","volume":"11","author":"Bulnes","year":"2024","journal-title":"Front. Cardiovasc Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119301_bib48","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.biopha.2026.119301_bib49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11883-024-01241-3","article-title":"Targeting inflammatory pathways in atherosclerosis: exploring new opportunities for treatment","volume":"26","author":"d'Aiello","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"issue":"23","key":"10.1016\/j.biopha.2026.119301_bib50","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur. Heart J."},{"issue":"38","key":"10.1016\/j.biopha.2026.119301_bib51","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.15420\/ecr.2018.11.1","article-title":"Role of anti-inflammatory interventions in coronary artery disease: understanding the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"13","author":"Lorenzatti","year":"2018","journal-title":"Eur. Cardiol."},{"key":"10.1016\/j.biopha.2026.119301_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front Cardiovasc Med."},{"issue":"24","key":"10.1016\/j.biopha.2026.119301_bib54","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1182\/bloodadvances.2023011578","article-title":"Effects of IL-1\u03b2 inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial","volume":"7","author":"Woo","year":"2023","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.biopha.2026.119301_bib55","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jacbts.2023.03.017","article-title":"Inflammasome signaling, thromboinflammation, and venous thromboembolism","volume":"8","author":"Potere","year":"2023","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119301_bib56","article-title":"Bridging inflammation and venous thrombosis: the NLRP3 inflammasome connection","volume":"12","author":"Wu","year":"2025","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10.1016\/j.biopha.2026.119301_bib57","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/ATVBAHA.122.317162","article-title":"Thromboinflammation: from atherosclerosis to COVID-19","volume":"42","author":"Wagner","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119301_bib58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"issue":"48","key":"10.1016\/j.biopha.2026.119301_bib59","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1093\/eurheartj\/ehx723","article-title":"Canakinumab for residual inflammatory risk","volume":"38","author":"Ridker","year":"2017","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.biopha.2026.119301_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157788","article-title":"Targeting IL-1\u03b2 as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer","volume":"7","author":"Yuan","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib61","article-title":"The role of interleukin 1\u03b2 in the pathogenesis of lung cancer","volume":"1","author":"Garon","year":"2020","journal-title":"JTO Clin. Res Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40364-021-00341-5","article-title":"Targeting interleukin-1\u03b2 and inflammation in lung cancer","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119301_bib63","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/19420862.2015.1081323","article-title":"The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1\u03b2","volume":"7","author":"Rondeau","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2026.119301_bib64","unstructured":"DrugBank. (2026). Canakinumab \u2013 Mechanism and pharmacokinetics. Retrieved January 6, 2026, from \u3008https:\/\/go.drugbank.com\/drugs\/DB06168\u3009."},{"issue":"6","key":"10.1016\/j.biopha.2026.119301_bib65","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib66","first-page":"5","article-title":"Anti-IL-1\u03b2 therapy lowers leukocyte supply and uptake in atherosclerosis","volume":"19","author":"Fern\u00e1ndez-Ruiz","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119301_bib67","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/MCA.0000000000000625","article-title":"Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"29","author":"Ali","year":"2018","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.biopha.2026.119301_bib68","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2020.51","article-title":"Anti-inflammatory treatment and cardiovascular outcomes: results of clinical trials","volume":"16","author":"Lorenzatti","year":"2021","journal-title":"Eur. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","article-title":"Colchicine in cardiovascular disease: in-depth review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"issue":"E","key":"10.1016\/j.biopha.2026.119301_bib70","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1093\/eurheartj\/suab084","article-title":"Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine","volume":"23","author":"Andreotti","year":"2021","journal-title":"Eur. Heart J. Suppl."},{"issue":"10289","key":"10.1016\/j.biopha.2026.119301_bib71","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2026.119301_bib72","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/molecules26040976","article-title":"NLRP3 inflammasome inhibitors in cardiovascular diseases","volume":"26","author":"Mezzaroma","year":"2021","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.biopha.2026.119301_bib73","doi-asserted-by":"crossref","first-page":"H1575","DOI":"10.1152\/ajpheart.00577.2025","article-title":"Clonal hematopoiesis of indeterminate potential: a unifying mechanism linking metainflammation and cardiometabolic diseases","volume":"329","author":"Wimalarathne","year":"2025","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"18","key":"10.1016\/j.biopha.2026.119301_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168597","article-title":"Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk","volume":"133","author":"Yu","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"26","key":"10.1016\/j.biopha.2026.119301_bib75","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119301_bib76","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J. Mol. Cell Cardiol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119301_bib77","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCULATIONAHA.118.034392","article-title":"CHIP (Clonal Hematopoiesis of Indeterminate Potential): potent and newly recognized contributor to cardiovascular risk","volume":"138","author":"Libby","year":"2018","journal-title":"Circulation"},{"issue":"6327","key":"10.1016\/j.biopha.2026.119301_bib78","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119301_bib79","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1253\/circj.CJ-18-0871","article-title":"Clonal hematopoiesis and its impact on cardiovascular disease","volume":"83","author":"Sano","year":"2018","journal-title":"Circ. J."},{"issue":"2","key":"10.1016\/j.biopha.2026.119301_bib80","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.biopha.2026.119301_bib81","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41577-018-0065-8","article-title":"Cardioimmunology: the immune system in cardiac homeostasis and disease","volume":"18","author":"Swirski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"7293","key":"10.1016\/j.biopha.2026.119301_bib82","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.biopha.2026.119301_bib83","first-page":"819","article-title":"Cell-intrinsic effects of clonal hematopoiesis in heart failure","volume":"2","author":"Abplanalp","year":"2023","journal-title":"Nat. Cardiovasc Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119301_bib84","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/s44161-024-00579-w","article-title":"Clonal hematopoiesis-related mutant ASXL1 promotes atherosclerosis in mice via dysregulated innate immunity","volume":"3","author":"Sato","year":"2024","journal-title":"Nat. Cardiovasc Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119301_bib85","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20250153","article-title":"Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis","volume":"222","author":"Zhou","year":"2025","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119301_bib86","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1\u03b2\/NLRP3 Inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2026.119301_bib87","first-page":"137","article-title":"Clonal haematopoiesis: Connecting ageing and inflammation in cardiovascular disease","volume":"17","author":"Jaiswal","year":"2020"},{"key":"10.1016\/j.biopha.2026.119301_bib88","first-page":"1867","article-title":"Inflammation and its resolution as determinants of acute coronary syndromes","volume":"114","author":"Libby","year":"2014"},{"issue":"22","key":"10.1016\/j.biopha.2026.119301_bib89","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.biopha.2026.119301_bib90","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.biopha.2026.119301_bib91","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCRESAHA.120.317104","article-title":"Clonal Hematopoiesis-Driver DNMT3A Mutations Alter Immune Cells in Heart Failure","volume":"128","author":"Abplanalp","year":"2021","journal-title":"Circ. Res"},{"issue":"12","key":"10.1016\/j.biopha.2026.119301_bib92","first-page":"1082","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"70","author":"Ib\u00e1nez","year":"2017","journal-title":"Rev. Esp. Cardiol. (Engl. Ed."},{"issue":"2","key":"10.1016\/j.biopha.2026.119301_bib93","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamacardio.2018.4566","article-title":"Cost-effectiveness of Canakinumab for prevention of recurrent cardiovascular events","volume":"4","author":"Sehested","year":"2019","journal-title":"JAMA Cardiol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:57:42Z","timestamp":1779245862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226003343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":93,"alternative-id":["S0753332226003343"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119301","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune\u2013endothelial crosstalk in cardiovascular inflammation: Canakinumab at the intersection of mechanism and precision therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119301"}}